Boston Scientific announced the acquisition of two technologies, a re-entry catheter from S.I. Therapies and an intraluminal CTO crossing device from ReVascular Therapeutics, both devices are used for the treatment of peripheral chronic total occlusions (CTOs).
Chronic total occlusion devices permit endovascular treatment in cases that otherwise might require a patient to undergo surgery or lower extremity amputation. By offering both a re-entry and intraluminal crossing device, Boston Scientific will be well positioned to help physicians address the challenges of treating complex peripheral lesions.
“Having used both devices, I am impressed with their simplicity and effectiveness,” said Dierk Scheinert, Heart Center Leipzig, and professor of Medicine at the University of Leipzig. “Access to these technologies will greatly enhance therapeutic options and provide physicians with new, intuitive solutions for treating challenging CTOs.”
“The purchase of these innovative CTO technologies demonstrates a continued commitment to expanding our peripheral interventions business,” said Joe Fitzgerald, senior vice president and president of Boston Scientific’s Endovascular Unit. “Not only will they augment our products for treating patients with lower extremity peripheral artery disease, but they will strengthen our clinical relationships with customers by offering them additional ways to deliver patient care.”
Together, the transactions are expected to have an immaterial impact on GAAP and adjusted earnings in 2011 and 2012 and be accretive thereafter. The company did not disclose transactional financial terms.
Boston Scientific said that the devices are expected to be launched in approved markets later this year.
